COVIVIO (COV.PA) Fundamental Analysis & Valuation

EPA:COV • FR0000064578

Current stock price

55.25 EUR
-1.1 (-1.95%)
Last:

This COV.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. COV.PA Profitability Analysis

1.1 Basic Checks

  • COV had positive earnings in the past year.
  • COV had a positive operating cash flow in the past year.
  • Of the past 5 years COV 4 years were profitable.
  • Of the past 5 years COV 4 years had a positive operating cash flow.
COV.PA Yearly Net Income VS EBIT VS OCF VS FCFCOV.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B -1B

1.2 Ratios

  • COV has a Return On Assets (1.63%) which is in line with its industry peers.
  • The Return On Equity of COV (5.08%) is comparable to the rest of the industry.
  • The Return On Invested Capital of COV (3.21%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA 1.63%
ROE 5.08%
ROIC 3.21%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
COV.PA Yearly ROA, ROE, ROICCOV.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10

1.3 Margins

  • COV has a Profit Margin (30.46%) which is in line with its industry peers.
  • In the last couple of years the Profit Margin of COV has grown nicely.
  • COV's Operating Margin of 57.81% is on the low side compared to the rest of the industry. COV is outperformed by 62.79% of its industry peers.
  • In the last couple of years the Operating Margin of COV has grown nicely.
  • COV has a Gross Margin (74.42%) which is comparable to the rest of the industry.
  • COV's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 57.81%
PM (TTM) 30.46%
GM 74.42%
OM growth 3Y11.41%
OM growth 5Y7.53%
PM growth 3Y16.3%
PM growth 5Y17.87%
GM growth 3Y2.18%
GM growth 5Y0.71%
COV.PA Yearly Profit, Operating, Gross MarginsCOV.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. COV.PA Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), COV is destroying value.
  • COV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
COV.PA Yearly Shares OutstandingCOV.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
COV.PA Yearly Total Debt VS Total AssetsCOV.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

  • COV has an Altman-Z score of 0.54. This is a bad value and indicates that COV is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of COV (0.54) is worse than 69.77% of its industry peers.
  • COV has a debt to FCF ratio of 28.49. This is a negative value and a sign of low solvency as COV would need 28.49 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 28.49, COV is doing worse than 62.79% of the companies in the same industry.
  • COV has a Debt/Equity ratio of 1.07. This is a high value indicating a heavy dependency on external financing.
  • COV's Debt to Equity ratio of 1.07 is on the low side compared to the rest of the industry. COV is outperformed by 76.74% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF 28.49
Altman-Z 0.54
ROIC/WACC0.55
WACC5.81%
COV.PA Yearly LT Debt VS Equity VS FCFCOV.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B 10B

2.3 Liquidity

  • A Current Ratio of 0.76 indicates that COV may have some problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 0.76, COV is in the better half of the industry, outperforming 65.12% of the companies in the same industry.
  • COV has a Quick Ratio of 0.76. This is a bad value and indicates that COV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • COV has a Quick ratio of 0.69. This is in the better half of the industry: COV outperforms 65.12% of its industry peers.
Industry RankSector Rank
Current Ratio 0.76
Quick Ratio 0.69
COV.PA Yearly Current Assets VS Current LiabilitesCOV.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. COV.PA Growth Analysis

3.1 Past

  • COV shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.26%.
  • Measured over the past 5 years, COV shows a small growth in Earnings Per Share. The EPS has been growing by 2.44% on average per year.
  • COV shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -11.71%.
  • The Revenue has been decreasing by -2.03% on average over the past years.
EPS 1Y (TTM)6.26%
EPS 3Y1.22%
EPS 5Y2.44%
EPS Q2Q%6.28%
Revenue 1Y (TTM)-11.71%
Revenue growth 3Y-8.88%
Revenue growth 5Y-2.03%
Sales Q2Q%40.47%

3.2 Future

  • Based on estimates for the next years, COV will show a small growth in Earnings Per Share. The EPS will grow by 3.42% on average per year.
  • COV is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.90% yearly.
EPS Next Y2.32%
EPS Next 2Y3.02%
EPS Next 3Y3.42%
EPS Next 5YN/A
Revenue Next Year4.94%
Revenue Next 2Y5.27%
Revenue Next 3Y9.9%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
COV.PA Yearly Revenue VS EstimatesCOV.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M 800M 1B
COV.PA Yearly EPS VS EstimatesCOV.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

5

4. COV.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 11.63 indicates a reasonable valuation of COV.
  • Based on the Price/Earnings ratio, COV is valued a bit cheaper than the industry average as 67.44% of the companies are valued more expensively.
  • When comparing the Price/Earnings ratio of COV to the average of the S&P500 Index (25.70), we can say COV is valued rather cheaply.
  • A Price/Forward Earnings ratio of 11.37 indicates a reasonable valuation of COV.
  • COV's Price/Forward Earnings is on the same level as the industry average.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 23.84, COV is valued rather cheaply.
Industry RankSector Rank
PE 11.63
Fwd PE 11.37
COV.PA Price Earnings VS Forward Price EarningsCOV.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, COV is valued a bit cheaper than the industry average as 65.12% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of COV is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 15.71
EV/EBITDA 17.07
COV.PA Per share dataCOV.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates COV does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)5.01
PEG (5Y)4.76
EPS Next 2Y3.02%
EPS Next 3Y3.42%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. COV.PA Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 6.65%, COV is a good candidate for dividend investing.
  • COV's Dividend Yield is a higher than the industry average which is at 5.28.
  • COV's Dividend Yield is rather good when compared to the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 6.65%

5.2 History

  • The dividend of COV decreases each year by -1.54%.
Dividend Growth(5Y)-1.54%
Div Incr Years2
Div Non Decr Years2
COV.PA Yearly Dividends per shareCOV.PA Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3 4

5.3 Sustainability

  • 92.76% of the earnings are spent on dividend by COV. This is not a sustainable payout ratio.
DP92.76%
EPS Next 2Y3.02%
EPS Next 3Y3.42%
COV.PA Yearly Income VS Free CF VS DividendCOV.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M -1B
COV.PA Dividend Payout.COV.PA Dividend Payout, showing the Payout Ratio.COV.PA Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

COV.PA Fundamentals: All Metrics, Ratios and Statistics

COVIVIO

EPA:COV (3/13/2026, 7:00:00 PM)

55.25

-1.1 (-1.95%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryDiversified REITs
Earnings (Last)02-18
Earnings (Next)07-20
Inst Owners41.1%
Inst Owner ChangeN/A
Ins Owners0.27%
Ins Owner ChangeN/A
Market Cap6.17B
Revenue(TTM)1.15B
Net Income(TTM)417.86M
Analysts75
Price Target64.28 (16.34%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 6.65%
Yearly Dividend0.72
Dividend Growth(5Y)-1.54%
DP92.76%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.73%
PT rev (3m)-0.67%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)1.67%
EPS NY rev (3m)1.57%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.21%
Revenue NY rev (3m)3.58%
Valuation
Industry RankSector Rank
PE 11.63
Fwd PE 11.37
P/S 4.5
P/FCF 15.71
P/OCF 6.15
P/B 0.75
P/tB 0.78
EV/EBITDA 17.07
EPS(TTM)4.75
EY8.6%
EPS(NY)4.86
Fwd EY8.8%
FCF(TTM)3.52
FCFY6.37%
OCF(TTM)8.99
OCFY16.27%
SpS12.29
BVpS73.66
TBVpS70.57
PEG (NY)5.01
PEG (5Y)4.76
Graham Number88.73
Profitability
Industry RankSector Rank
ROA 1.63%
ROE 5.08%
ROCE 3.59%
ROIC 3.21%
ROICexc 3.42%
ROICexgc 3.48%
OM 57.81%
PM (TTM) 30.46%
GM 74.42%
FCFM 28.62%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y11.41%
OM growth 5Y7.53%
PM growth 3Y16.3%
PM growth 5Y17.87%
GM growth 3Y2.18%
GM growth 5Y0.71%
F-Score7
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF 28.49
Debt/EBITDA 9.39
Cap/Depr 415.79%
Cap/Sales 44.53%
Interest Coverage 250
Cash Conversion 106.76%
Profit Quality 93.95%
Current Ratio 0.76
Quick Ratio 0.69
Altman-Z 0.54
F-Score7
WACC5.81%
ROIC/WACC0.55
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.26%
EPS 3Y1.22%
EPS 5Y2.44%
EPS Q2Q%6.28%
EPS Next Y2.32%
EPS Next 2Y3.02%
EPS Next 3Y3.42%
EPS Next 5YN/A
Revenue 1Y (TTM)-11.71%
Revenue growth 3Y-8.88%
Revenue growth 5Y-2.03%
Sales Q2Q%40.47%
Revenue Next Year4.94%
Revenue Next 2Y5.27%
Revenue Next 3Y9.9%
Revenue Next 5YN/A
EBIT growth 1Y-0.73%
EBIT growth 3Y1.52%
EBIT growth 5Y5.34%
EBIT Next Year7.24%
EBIT Next 3Y6.63%
EBIT Next 5YN/A
FCF growth 1Y-30.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-7.27%
OCF growth 3YN/A
OCF growth 5YN/A

COVIVIO / COV.PA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for COVIVIO?

ChartMill assigns a fundamental rating of 3 / 10 to COV.PA.


What is the valuation status for COV stock?

ChartMill assigns a valuation rating of 5 / 10 to COVIVIO (COV.PA). This can be considered as Fairly Valued.


Can you provide the profitability details for COVIVIO?

COVIVIO (COV.PA) has a profitability rating of 4 / 10.


What is the financial health of COVIVIO (COV.PA) stock?

The financial health rating of COVIVIO (COV.PA) is 1 / 10.


How sustainable is the dividend of COVIVIO (COV.PA) stock?

The dividend rating of COVIVIO (COV.PA) is 4 / 10 and the dividend payout ratio is 92.76%.